The QualityStocks Daily Monday, November 19th, 2018

Today's Top 3 StockMarketWatch

StockMarketWatch (AKER) +42.28%

QualityStocks (COSM) +19.35%

Trading Concepts (LEJU) +17.75%

The QualityStocks Daily Stock List


Penny Stock Tweets, Market Screener, Wallet Investor, InvestorsHub, Micro Cap Daily, Equities, Barchart, StockInvest, Advanced Equity Research, Green Market Report, TipRanks, The Street, FXStreet, Micro Small Cap, YCharts, 4-Traders, Capital Cube, Street Register, TradingView, Investor Place, Insider Financial, Stockhouse, MarketWatch, and Finance Registrar reported earlier on WEED, Inc. (BUDZ), and we also report on the Company, here at the QualityStocks Daily Newsletter.

WEED, Inc. is a multi-national, multi-faceted, vertically-integrated world class cannabis organization. Its dedication is to its global objectives and outreach across the full spectrum of the cannabis industry to find treatments, therapies as well as medical cures using the Cannabaceae plant family. WEED has established WEED Israel (Cannabis) Ltd. as a wholly-owned subsidiary of WEED, Inc (USA). WEED is based in Tucson, Arizona and the Company lists on the OTCQB.

WEED is structured as a holding company. It does business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote its global brand. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act. In addition, the Company meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locales.

WEED has purchased a 4-acre property in La Veta, Colorado. This is where the Company’s wholly-owned subsidiary, Sangre AgroTech, is engaged in the earlier announced 5-year, $15-plus million Cannabis Genomic Study. In association with the La Veta property, WEED received unanimous approval of the La Veta Town Council for a Commercial Redevelopment Permit to start planned renovations and construction of the Bioscience Research Center for the operations of Sangre AgroTech to convert the existing buildings into laboratory facilities needed for Sangre to conduct its research, along with additional security and ground buildout.

Sangre AT, LLC, dba Sangre AgroTech, has begun a five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, through creating an international genomic classification of the entire plant. By targeting cannabis-derived molecules that stimulate the endocannabinoid system, Sangre AgroTech’s research team plans to develop scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines. The goal of this research is to identify, collect, patent, as well as archive a collection of highly-active medicinal strains.

Last month, WEED announced that it acquired the rights to two trademark registrations directed to the name of the company, WEED. The purchases are part of a wider effort by the Company to expand its Intellectual Property (IP) Brands Division into an array of goods and services outside those offered as part of its core goods and services, specifically, the development of cannabis–derived healthcare & adult use Cannabis products. Among other measures, WEED has sought to expand WEED™ and other associated brands including WEED RULES!™ to goods and services, which include cosmetics and cleaning preparations, paper goods and printed matter, and natural agricultural products in addition to others via the filing of numerous trademark applications in the United States Patent and Trademark Office (USPTO).

WEED, Inc. (BUDZ), closed Monday's trading session at $2.14, down 6.14%, on 44,566 volume with 42 trades. The average volume for the last 3 months is 219,946 and the stock's 52-week low/high is $1.72/$15.19.



RedChip, PricelessPenny, SmallCapVoice, 1-2-3 Stock Alerts, Money Morning, Fortune Stock Alerts, Penny Stock Circle, Value Penny Stocks,, StockMister, PennyPro, Stock Commander, HotStockProfits, AddictivePennyStocks,,, PennyStocks Forever, and TheMicrocapNews reported on BTCS, Inc. (BTCS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, BTCS, Inc. is a blockchain technology company based in Silver Spring, Maryland. The Company is an early entrant in the Digital Asset market. It is also one of the first U.S. publicly traded companies engaged with Digital Assets and blockchain technologies. The Company has a record of accomplishment of accurate digital asset trend prediction. Blockchains are distributed public ledgers that can fundamentally influence all industries around the world that require trust and rely on or use record keeping.

A blockchain is secured and maintained by a network of specialized servers (nodes) internationally. All transactions are publicly available on a blockchain. Transactions undergo verification and confirmation by way of nodes worldwide before being added to a blockchain.

BTCS’ plan (subject to additional financing) is to create a portfolio of digital assets, such as bitcoin and other "protocol tokens", to provide investors a varied pure-play exposure to the bitcoin and blockchain industries. The Company’s intention is to acquire digital assets via open market purchases; and participate in initial digital asset offerings (or initial coin offerings).

In addition, BTCS may acquire digital assets through resuming its transaction verification services business (or mining) through outsourced data centers and earning rewards in digital assets by securing their respective blockchains. Furthermore, the Company is focusing on growth through acquisition.

This past August, BTCS announced it signed a non-binding Letter of Intent (LOI) to merge with Blockchain Global Limited (BCG), an Australian blockchain company. BCG operates four different business lines. These include an institutional exchange platform, transaction verification services (bitcoin mining), a blockchain start-up accelerator, and a blockchain technology consultancy.

Recently, BTCS announced it secured $1,000,000 in financing. This includes $250,000 (59.38) in bitcoin. Mr Charles Allen, BTCS Chief Executive Officer, said, “This financing represents a major milestone in the ongoing evolution of our Company. With the opportunity in the burgeoning blockchain space is still in its infancy, our planned merger with Blockchain Global Ltd. (BGL) positions us with a diversified business model that sets the stage for market leadership globally, and this financing represents a strong commitment to move forward.”

In October, BTCS announced it closed on the remaining balance of its earlier announced financing that was co-led by Blockchain Global Ltd. (BGL). The Company received a total of $1.1 million from the sale of its Series C -1 Convertible Preferred Stock (the C-1) and Warrants.

BTCS, Inc. (BTCS), closed Monday's trading session at $0.0245, up 16.67%, on 2,526,205 volume with 156 trades. The average volume for the last 3 months is 1,782,625 and the stock's 52-week low/high is $0.019/$0.307.


Asia Equity Exchange Group, Inc. (AEEX)

OTC Markets, InvestorsHub, and MarketWatch reported on Asia Equity Exchange Group, Inc. (AEEX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Asia Equity Exchange Group, Inc. is working to establish and build an equity information service platform designed to provide equity investment financing information to all enterprises in the nations and regions of Asia. Asia Equity Exchange Group, with its website, invested and operated by Asian Equity Exchange Group Co., Ltd., is an intercontinental equity exchange and a service platform for companies in Asia to release equity investment and financing information.

Asia Equity Exchange Group has offices in Kowloon Bay, Hong Kong; Shenzhen, China; and New York, New York. The Company lists on the OTC Markets Group’s OTCQB.

The operating structure of the Company is: Asia Equity Exchange Group, Inc. 100 percent shareholding Asian Equity Exchange Group Co. Ltd. 100 percent shareholding AEEX (HK) International Financial Services Limited 100 percent shareholding Asian & American Consultant (Shenzhen) Co. Ltd.

In essence, Asia Equity Exchange Group integrates worldwide capital and works with providers of a broad array of services. The Company provides growing and innovative companies with diversified and professional services, and global professional investors with quality, open, and diverse investment opportunities. It serves as a significant part and a vital link of the multi-layered capital markets in Asia. Asia Equity Exchange Group enables companies to obtain the resources to successfully launch their IPO (Initial Public Offering).

Asia Equity Exchange Group helps companies develop in a sustainable manner. Furthermore, the Company introduces high-value investment markets to professional institutional and individual investors.

In addition, it aims to create a unique and authoritative intercontinental equity information platform, which effectively complements business functions, service means and financing channels with OTC markets in different nations and regions.

Asia Equity Exchange Group is also working to build a system of intercontinental cooperation to provide listed enterprises with equity financing means through domestic and out of the country channels, and to provide nurturing, pre-listing tutoring, and incubating, and also supporting services for their listing on overseas capital markets by shifting boards.

Asia Equity Exchange Group introduces global securities and institutional investors in its shareholder structure. Moreover, it partners with international organizations in its operations. These include investment banks, financial and legal institutions, and professional consulting teams.

In December, Asia Equity Exchange Group hosted a media event at the Hilton Shenzhen Futian, announcing the successful financing of $15 million USD for a private placement deal. The AEEX management team and guest speakers examined the development of the private placement process and discussed how Chinese SMEs (small and medium sized enterprises) can develop faster and more effective methods to operate in capital markets.

Asia Equity Exchange Group, Inc. (AEEX), closed Monday's trading session at $8.99, up 1.93%, on 44,566 volume with 116 trades. The average volume for the last 3 months is 219,946 and the stock's 52-week low/high is $3.21/$8.99.


GelTech Solutions, Inc. (GLTC)

BullRally, InvestorPlace, CoolPennyStocks, HotOTC, SmallCapVoice, TheMicrocapNews, Investor Relations, OTC Picks, PennyTrader Publisher, Wise Alerts, CRWEFinance, and Stock Rich reported previously on GelTech Solutions, Inc. (GLTC), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

GelTech Solutions, Inc. is a leading provider of unique, environmentally friendly, and cost-effective products. These products help government agencies, industry, agriculture, and the public reach goals, including water conservation and protecting lives, homes and property from fires. GelTech is an innovator in the use of environmentally-friendly polymers for fire suppression and protection. The Company is based in Jupiter, Florida.

GelTech Solutions has its FireIce Wildland Fire Division. It specializes in providing innovative fire chemicals and equipment, and also industry-leading training and support, to wildland fire agencies globally.

GelTech Solutions’ products include Fire Suppression, Industrial Absorbents, and Soil Amendments. FireIce® is a firefighting product. FireIce is in use at manifold fire departments throughout the nation as a supplement to their fire suppression equipment. FireIce has been approved by the United States Forest Service for use on the ground and from the air to suppress oncoming wildland fires.

FireIce® is a non-toxic dry polymer. When mixed with water it becomes a very effective and versatile gel used by wildland and municipal firefighting agencies as a suppressant to extinguish fires and as a fire retardant to protect assets and property. Additionally, FireIce can suppress specifically challenging manhole, tire, magnesium and other fires more than 10,000 degrees Fahrenheit. It can also suppress electrical fires of up to 50,000 volts.

GelTech Solutions is working with a number of industrial clients that are incorporating FireIce Shield® into their manufacturing process. This is to prevent fires and avoid expensive business interruptions while processing flammable materials.

GelTech Solution’s Soil2O Dust Control and Soil Cap are cost effective, polymer-based products. The construction and mining industries, farmers and local communities use these products to reduce airborne particulate matter with minimal environmental impact.

Soil2O Topical and Soil2O Granular are a line of moisture retention products. They are used in agriculture, commercial landscaping and by homeowners to improve crop, plant, and lawn health while lessening water usage by up to 50 percent.

The Company also has its GT-W14. This is an advanced absorbency technology. It is used by manufacturers, shippers, and auto maintenance facilities to control industrial fluid spills of all sizes, turning liquids into solid waste for easier and safer disposal.

This past June, GelTech Solutions announced that the FireIce Wildland Fire Division secured two new geographically dispersed western state firefighting agencies for the evaluation of FireIce products in airtankers. The agencies are running pilot programs that include the evaluation of new state-of-the-art tanker base loading equipment. Furthermore, the FireIce Wildland Fire Division is supporting the Oregon Department of Forestry for the third straight season, and Saskatchewan Northern Air Operations and Washington Department of Natural Resources for the second season.

GelTech Solutions has launched its FireIce Lithium Battery Active Suppression Kit. It automatically detects elevated temperatures releasing FireIce ST, a special blend of FireIce, to the affected battery module, to cool and suppress the batteries and prevent the system from reaching runaway that could cause an explosion. The design of the kit is to deliver FireIce ST product only to the battery compartment where it is required, leaving other compartments untouched.

GelTech Solutions, Inc. (GLTC), closed Monday's trading session at $0.1677, up 12.17%, on 41,650 volume with 10 trades. The average volume for the last 3 months is 13,085 and the stock's 52-week low/high is $0.102/$0.478.


Cosmos Holdings, Inc. (COSM)

OTC Markets, Barchart, Street Insider, InvestorsHub, 4-Traders, BusinessWire, Marketwired, and Capital Cube reported on Cosmos Holdings, Inc. (COSM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A pharmaceutical company, Cosmos Holdings, Inc. concentrates on identifying, acquiring, developing, and commercializing medicines to improve patients' lives and outcomes. The Company has offices and distribution centers in Thessaloniki, Greece & in Harlow, UK (United Kingdom). Cosmos Holdings lists on the OTC Markets Group’s OTCQB. The Company has its head office in Chicago, Illinois.

Cosmos Holdings specializes, by way of its subsidiaries, in the wholesale of pharmaceutical products across Europe. It has a trans-European network of greater than 110 clients and vendors in Germany, the UK, United Arab Emirates (UAE), Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands, and Greece.

The Company’s subsidiaries include Sky Pharm SA (Thessaloniki, Greece). Sky Pharm trades the excess amounts of approximately 500 medicines, which can be exported within the European Union (EU) countries.

Another subsidiary is Decahedron Ltd. Decahedron is a pharmaceutical wholesaler. It imports and exports branded, generic, and unlicensed POM, OTCs, and medical devices all around the world.

Areas that Cosmos Holdings is concentrating on include Branded & Over the Counter (OTC) Pharmaceuticals; Generic Pharmaceuticals; Cosmetics Products & Food Supplements; Research & Development (R&D); and Growth Opportunities.

Regarding Generic Pharmaceuticals, the Company focuses on acquiring dossiers and registrations for generic products that require limited manufacturing start-up and development activities.

Pertaining to Cosmetics Products & Food Supplements, the Company’s focus is investing in high growth business segments with durable revenue streams and, where possible and capable, geographical expansion and penetration.

This past January, Cosmos Holdings, via its wholly-owned subsidiary Sky Pharm S.A., announced its agreement with Doc Pharma S.A.  The agreement with Doc Pharma S.A. (cGMP) outlines the development and contract manufacturing of Cosmos Holdings' total line of food supplements.

With this agreement, Doc Pharma S.A. will research, develop formulation, design product packaging, complete product registration, and provide market-ready products.  Doc Pharma S.A. is a Greece-based (cGMP) licensed contract manufacturer with production facilities in Athens, Greece. 

Cosmos Holdings, Inc. (COSM), closed Monday's trading session at $7.40, up 19.35%, on 2,869 volume with 21 trades. The average volume for the last 3 months is 2,660 and the stock's 52-week low/high is $3.00/$12.50.


Assure Holdings Corp. (ARHH)

Stockhouse, Streetwise Reports, OTC Markets, and Barchart reported on Assure Holdings Corp. (ARHH), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Assure Holdings Corp. works with neurosurgeons and orthopedic spine surgeons to provide a turnkey group of services that support intraoperative neuro-monitoring activities during invasive surgeries. The Company focuses primarily on supporting spinal surgeries. However, Assure has plans in place to support other classes of medicine that rely on the standard of care that intraoperative neuro-monitoring provides.

Assure Holdings, together with its subsidiaries, delivers technical and professional surgical support services in association with intraoperative neuro-monitoring procedures (IONM). Assure has its headquarters in Parker, Colorado. The Company lists on the OTC Markets Group’s OTCQB.

Intraoperative Neurophysiological Monitoring (IONM) is used to monitor patients’ unique neural functions associated with the brain, spinal cord, and peripheral nerves. Assure has a highly skilled staff that can cover cases ranging from spinal cord monitoring to complicated intracranial brain function mapping.

The aim of IONM is to identify changes in brain, spinal cord, and/or peripheral nerve function. This is to prevent complications that could result in irreversible nerve damage.

Assure employs its own staff of technologists. The Company also utilizes its own state-of-the-art monitoring equipment. Assure handles 100 percent of intraoperative neuromonitoring scheduling and setup, and bills for the provision of all technical services.

Monitoring procedures include Neurological Surgery – aneurysms, brain tumors, cervical fusion, lumbar fusion, peripheral nerve exploration, and resection of spinal cord tumors. In addition, monitoring procedures include Otolaryngology Surgery – acoustic neuroma, parotidectomy, as well as tympanomastoidectomy.

Furthermore, monitoring procedures include Orthopedic Surgery – acetabular fractures, cervical fusion, lumbar fusion, scoliosis correction, spinal deformity, thoracic fusion, total hip replacement and revision, and shoulder replacements.

This month, Assure announced that Mr. John A. Farlinger (CPA, CA), a Board member and the current Chair of the Audit Committee was appointed the Executive Chairman and Interim Chief Executive Officer of the Company, effective immediately. This is following the resignation of Mr. Preston Parsons, the Founder and now former Chairman and Chief Executive Officer of Assure Holdings.

Mr. Parsons will remain as a Board member of Assure. He will focus exclusively on working to generate increased revenue through engaging new surgeons to its platform, executing on Assure’s multi-state expansion strategy, and concentrating on expanding Assure’s intraoperative neuromonitoring services to ENT, Cardiovascular and other highly invasive surgeries.

Assure Holdings Corp. (ARHH), closed Monday's trading session at $1.709, up 4.18%, on 2,376 volume with 6 trades. The average volume for the last 3 months is 4,936 and the stock's 52-week low/high is $1.00/$3.447.


OWC Pharmaceutical Research Corp. (OWCP)

OTC Markets, Promotion Stock Secrets, Street Register, The Profit Buzz, CFN Media Group, Insider Financial, The Street, Stock Invest, TipRanks and Cannabis Financial Network News reported earlier on OWC Pharmaceutical Research Corp. (OWCP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OWC Pharmaceutical Research Corp. engages in the research and development (R&D) of cannabis-based medical products. The OTCQB-listed Company provides medical products for the treatment of diverse medical conditions and/or diseases. These include multiple myeloma, psoriasis, PTSD, migraines, and delivery systems. OWC Pharmaceutical Research is based in Petach Tikva, Israel. One World Cannabis Ltd. is a wholly-owned subsidiary of OWC Pharmaceutical Research.

The Company has entered into research and collaboration agreements with three of the top research institutions in Israel. These include Sheba Academic Medical Center, one of the leading academic hospitals in the Middle East. These agreements serve as the foundation for OWC’s clinical trials. They ensure that all of its studies have been, and will continue to be, based on established research protocols of the U.S. Food and Drug Administration (FDA), Institutional Review Boards, and Independent Ethical Committees.

OWC Pharmaceutical Research has completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the tablet is protected. It provides for the ingestion of almost any dosage of medical cannabis with a sublingual delivery mechanism, where the compounds are absorbed directly into the patient's blood via oral epithelial tissue.

Subsidiary One World Cannabis’ Research Division concentrates on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of different medical conditions. Its Consulting Division’s commitment is to helping governments and companies navigate complex global cannabis regulatory frameworks.

OWC has received the first ever Institutional Review Board (IRB) approval to conduct a safety study for a cannabis-based topical cream with greater than 3 percent THC. The Company is conducting a safety study (FDA Phase 1 equivalent) in one of the largest academic hospitals in Israel.

Last month, OWC Pharmaceutical Research announced that its newly developed, highly concentrated, delivery formulation, OWC-1808, was administered in vivo in an animal model for the first time and was found to be safe and tolerable. The formulation will permit the delivery of very high doses of CBD and THC with exceptional bioavailability. The continued development and testing of this formulation will be directed initially at the Company`s continuing program for treating Multiple Myeloma.

Dr. Stanley Hirsch, Chairman of OWC Pharmaceutical Research, said "This is an important milestone in our pre-clinical development of cannabis-based therapies for Multiple Myeloma… Cannabis-based therapies represent a new frontier in fighting this disease and this potentially moves cannabis from being a cancer palliative to becoming a cancer therapeutic".

OWC Pharmaceutical Research Corp. (OWCP), closed Monday's trading session at $0.148, down 6.03%, on 411,964 volume with 89 trades. The average volume for the last 3 months is 335,469 and the stock's 52-week low/high is $0.11/$0.665.


Golden Predator Mining Corp. (NTGSF)

Penny Stock Hub, 4-Traders, Mining Stock Valuator, Morningstar, Market Screener, OTC Markets, Stockhouse, Gold Investment Letter, Junior Mining Network, Barchart, The Street, Investors Hangout, and Dividend Investor reported previously on Golden Predator Mining Corp. (NTGSF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Golden Predator Mining Corp. acquires and explores for mineral properties in the United States and Canada. It concentrates on its district scale, orogenic gold-in-quartz 3 Aces Project in the Yukon. The Company formerly went by the name Northern Tiger Resources, Inc. It changed its corporate name to Golden Predator Mining Corp. in April 2014. OTCQX-listed, Golden Predator Mining has its head office in Vancouver, British Columbia.

The 100 percent owned 3 Aces Project is 357 km2 (35,700 hectares). It is a high-grade gold project (Orogenic Gold Model). The 3 Aces Project includes at least 6 mineralized areas. These are all situated within and along favorable stratigraphic and structural zones that extend more than 35km along trend. Several mineralized veins have been discovered so far. Many have visible gold occurrences. The 3 Aces Project hosts the two highest grade surface outcrops discovered to date in the Yukon.

Golden Predator Mining also holds 100 percent of the advanced Brewery Creek Project in the Yukon. The Brewery Creek Mine is operated by Golden Predator Mining. The target at the Brewery Creek Mine is an intrusion related gold deposit. The Brewery Creek Mine is 55km east of Dawson in the northwestern region of the Yukon.

This past September, Golden Predator Mining announced the successful completion of a 22 hole exploration and metallurgical drilling program at its 100 percent owned Brewery Creek Project in the Yukon, and repored on the results of the exploration drill program designed to expand the present resource.  Significant gold mineralization was encountered in 8 of the 9 exploration holes increasing known gold mineralization around five zones. These include Schooner, Sleeman, Lucky, Bohemian, and Lone Star.

Today, Golden Predator Mining reported that drilling of the extensive soil geochemical target in the Sprogge Area of the 3 Aces Project positioned in southeast Yukon has discovered an important new style of disseminated gold mineralization. The Sprogge Area discovery represents a potentially large gold-bearing intrusive system not previously encountered at the 3 Aces Project. For 2019, follow-up exploration of the new gold discovery is planned beginning with geophysical surveys designed to target blind intrusive-related gold mineralization at depth.

Golden Predator Mining Chairman, Mr. William Sheriff, said that the original aim for the Sprogge drilling was to find a continuation of the structurally-controlled Central Core Zone beneath the large geochemical anomaly. “We now feel confident that Sprogge is much higher in the stratigraphy than the Central Core Zone and the potential for the high-grade orogenic deposit lies below.``

Golden Predator Mining Corp. (NTGSF), closed Monday's trading session at $0.19994, up 0.22%, on 119,000 volume with 11 trades. The average volume for the last 3 months is 67,432 and the stock's 52-week low/high is $0.189/$0.743.


Bonterra Resources, Inc. (BTR.V)

OTC Markets, Stockwatch, Streetwise Reports, Stockhouse, InvestorsHub, Mining Feeds, TradingView, HotStocked, Barchart, Business Insider, 4-Traders, Resource World, Investors Hangout, and Penny Stock Hub reported earlier on Bonterra Resources, Inc. (BTR.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bonterra Resources, Inc. is a gold exploration company based in Vancouver, British Columbia. Currently, it is moving ahead with deposit extension and resource expansion in and around its new high-grade Gladiator Gold Deposit. The Company’s focus is to add ounces to the world class Abitibi Gold Belt in the Provinces of Quebec and Ontario. Bonterra Resources shares trade on the OTC Markets Group’s OTCQX.

Bonterra Resources`10,541-hectare Gladiator Gold Project is in the Urban-Barry Greenstone Belt within the Abitibi Subprovince. The Gladiator Deposit remains open in all directions with drilled dimensions presently outlined to a depth of 1,000 meters with a strike length of 1,200 meters. A minimum of six distinct subparallel zones or mineralized horizons have been identified.

This past July, the Company announced that further to its news release of May 23, 2018, it completed and entered into an Option Agreement with Beaufield Resources, Inc. Beaufield has granted Bonterra an option to acquire a 70 percent interest in 81 strategic mineral claims totaling 3,590 hectares, situated in the Urban Barry Greenstone belt, Quebec, and known as the Duke property.

Bonterra Resources also has its Larder Lake Gold Project. Larder Lake is 2,165-hectares. It is located in eastern Ontario, in McVittie and McGarry Townships, near the town of Virginiatown. Central to the Larder Lake Gold Property is the Cheminis property (the Cheminis Mine). Intermittent past production from the Cheminis Mine has totaled roughly 260,000 tons at a recovered grade of approximately 0.104 ounces Au/ton.

Bonterra Resources and Metanor Resources, Inc. announced in July 2018 that, further to their news release dated June 18, 2018, the two companies entered into a definitive arrangement agreement dated July 20, 2018, to combine Bonterra Resources and Metanor Resources to create a new advanced Canadian gold exploration and development company focused on becoming the leader in the building out and future mining development of the Urban Barry Quebec Gold Camp.

Last month, Gatling Exploration, Inc. reported that it received conditional approval of the listing of its common shares on the TSX Venture Exchange (TSX-V). Gatling filed on its TSX-V listing application and a technical report pertaining to the Larder Lake Property. The listing of Gatling follows the closing on September 24, 2018 , of a plan of arrangement between Bonterra Minerals, Inc. (BTR.V) (Bonterra) and Metanor Resources.  Immediately before completion of the Arrangement, all Bonterra shareholders of record on September 21, 2018 , received, for each Bonterra share held as of the record date, one-seventh of one common share of Gatling resulting in 33,426,512 Gatling Shares being issued.  Gatling received the transfer of certain Bonterra assets. This includes the Larder Lake Property and roughly $7,000,000 in cash. Bonterra's obligations related to the Larder Lake Property have now been assigned to and assumed by Gatling.

Also in October, Bonterra Resources provided an update following the completion of the acquisition of Metanor Resources. It plans to develop the exploration and mining assets in the Urban Barry. With the recent consolidation of mill, mine, pre-production and exploration assets, Bonterra`s intention is to speed up development of the Gladiator, Moroy and Barry deposits, while expanding the capacity of the Urban Barry Mill.

Bonterra Resources, Inc. (BTR.V), closed Monday's trading session at $3.05, down 1.61%, on 50,222 volume with 167 trades. The average volume for the last 3 months is 74,025 and the stock's 52-week low/high is $2.85/$7.19.


Cannabis Sativa, Inc. (CBDS)

Flagler Financial Group, TheMicrocapNews, TopStockAnalysts, Top Pros’ Top Picks, Insider Financial, Darwin Investing Network, Wall Street Mover, Stock Beast, Promotion Stock Secrets, Jason Bond,, TopPennyStockMovers, Stockgoodies, Cannabis Financial Network News, Greenbackers, smartOTC, and Real Pennies reported earlier on Cannabis Sativa, Inc. (CBDS), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Cannabis Sativa, Inc. engages in branding and licensing through its 'hi' intellectual properties. The Company engages, via its subsidiaries, Wild Earth Naturals and "hi" Brands International, Inc., in the research, development, and licensing of specialized natural products. These include formulas, edibles, topicals, recipes, as well as delivery systems. Cannabis Sativa has been active in pursuing Intellectual Property (IP). It has successfully acquired an increasing portfolio of IP. Cannabis Sativa is based in Mesquite, Nevada, and the Company lists on the OTCQB.

Cannabis Sativa brands, licenses, innovates, and markets premier plant-derived topical creams, transdermals, balms, sublinguals, lubricants, and edibles for medical and recreational marijuana consumers, and legal nutraceuticals and branded merchandise for consumers in general.

Cannabis Sativa looks for strategic partners for acquisition of operating companies, intellectual property (IP), and other assets that fit within its corporate vision. Also, the Company holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, and owns patent pending and trade secret formulas and processes.

The Company’s wholly-owned subsidiary, Hi Brands International, entered into an agreement with Centuria Natural Foods, Inc. to market their proprietary CBD Rich Hemp Oil products. Their CBD capsules are marketed under the name, "hi CBD."

Cannabis Sativa acquired a majority ownership interest in iBudtender, Inc., a Colorado corporation. In addition, it entered into an agreement to acquire a 49 percent ownership interest in a nine-acre property in Los Angeles County, California.

The ownership group’s intention is to lease the property to an industrial hemp farm operator. The operator will conduct farming activities under the Industrial Hemp provisions of California's Adult Use Marijuana Act (Prop 64).

Cannabis Sativa has its Wild Earth Naturals offerings. It offers the Wild Earth Naturals line of CBD Water and cosmetic products designed to use organic and natural ingredients. These include CBD and hemp seed oil.

The Company also entered into a license agreement for the manufacture, marketing, and sale of its White Rabbit products in California. It closed its acquisition of the White Rabbit brand of cannabis sprays and cannabis mints. The acquisition includes the exclusive and proprietary product formulations, product mixes, manufacturing methods, and also branding.

Cannabis Sativa acquired a controlling interest in PrestoCorp (a.k.a. PrestoDoctor). This is an online telemedicine platform. It provides access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation utilizing secure video conferencing technology. PrestoDoctor® is the top online medical marijuana recommendation service.

Cannabis Sativa’s PrestoDoctor® expanded to Pennsylvania on April 20, 2018. Greater than 3,800 people signed up in the medical marijuana patient registry's first week. The program will give those with one of 17 specific diagnoses access to cannabis starting in 2019.

PrestoDoctor® is addressing the lack of physicians with its #1 ranked telemedicine platform. This platform streamlines much of the process. Prospective patients fill out a short online application, choose an appointment time, and talk to a physician.

Cannabis Sativa, Inc. (CBDS), closed Monday's trading session at $4.00, down 1.72%, on 73,291 volume with 221 trades. The average volume for the last 3 months is 285,078 and the stock's 52-week low/high is $1.91/$9.74.


CTD Holdings, Inc. (CTDH)

Penny Stock Hub, Financial Content, Research Pool, Morningstar, Market Screener, Wallet Investor, HotStockChat, Capital Cube, Dividend Investor, Greenbackers, Wall Street Resources, Marketwired, Pink Investing, YCharts, Nebula Stocks, The Street, 4-Traders, Business Insider, and Guru Focus reported on CTD Holdings, Inc. (CTDH), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

CTD Holdings, Inc. is developing cyclodextrin-based products for the treatment of disease. This includes Trappsol® Cyclo™. Its other divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in the research, pharmaceutical, medical device, cosmetics, and nutrition markets. A biotechnology company, CTD Holdings is based in Alachua, Florida. The Company`s shares trade on the OTC Markets` OTCQB.

CTD’s Trappsol® Cyclo™ is an orphan drug designated product. It is for the treatment of Niemann-Pick Type C (NPC). This is a rare and frequently fatal genetic disease in young children. Furthermore, the disease results in significant health impairment for affected adults. NPC impacts the brain, lung, liver, spleen, and other organs. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. This includes peripheral artery disease, diabetic nephropathy, as well as acute viral infections.

CTD Holdings’ other divisions operate the world's only cGMP pulse drying facility to produce UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. Also, they supply cyclodextrins to biotechnology and life science researchers globally from the world's largest catalog of cyclodextrins.

CTD Holdings has started a multi-center international Phase I/II clinical trial in Europe. This clinical trial is evaluating intravenous administration of Trappsol® Cyclo™ in NPC patients.

This month, CTD Holdings announced its newest partner in support of its U.S. clinical program, Synteract. Synteract is a full-service Clinical Research Organization that has an existing relationship with CTD Holdings in support of its Phase I/II clinical trial at sites in Israel and Sweden.  Synteract will support CTD’s Extension Protocol, “An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol® Cyclo™ (HPBCD) in Patients with Niemann-Pick Disease Type C (NPC-1),” in the U.S.  CTD’s Extension Protocol for the Phase I trial was approved by the Food and Drug Administration (FDA) in April of this year.

Sharon H. Hrynkow, PhD, CTD Holdings’ Senior Vice President for Medical Affairs, said, “Synteract is now a critical part of CTD’s overall clinical program in the United States. As we continue to advance our formal clinical trials, the information gathered via this extension protocol will be useful to the FDA and to regulatory authorities in Europe and Israel as we seek market registration for Trappsol® Cyclo™.”

CTD Holdings, Inc. (CTDH), closed Monday's trading session at $0.955, down 9.05%, on 3,348 volume with 12 trades. The average volume for the last 3 months is 16,907 and the stock's 52-week low/high is $0.25/$1.18.


Northwest Biotherapeutics, Inc. (NWBO)

RedChip, WealthMakers, SmallCapVoice Wealthpire, CoolPennyStocks, StreetInsider, PureActionStocks, Promotion Stock Secrets, Wall Street Corner, BUYINS.NET, StockPicksNYC, Market Report, Pennybuster, The Street, FeedBlitz, AllPennyStocks, BullRally, Marketbeat, InvestorPlace, Streetwise Reports, and OTCPicks reported previously on Northwest Biotherapeutics, Inc. (NWBO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Northwest Biotherapeutics, Inc. is a biotechnology enterprise developing DCVax® personalized immune therapies for solid tumor cancers. In the U.S and Europe, its emphasis is on developing personalized immunotherapy products, on a cost-effective basis, designed to treat cancers more effectively than present treatments. This is without toxicities of the type associated with chemotherapies. OTCQB-listed, Northwest Biotherapeutics is headquartered in Bethesda, Maryland.

The Company has a wide-ranging platform technology for DCVax dendritic cell-based vaccines. Northwest is working to move forward with manifold clinical programs, involving DCVax-L and DCVax-Direct. Its lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). This trial has completed its enrolment.

Northwest Biotherapeutics is pursuing completion of the current Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer and pursuing Phase II combination trials of DCVax-L and checkpoint inhibitor drugs. This includes the Phase II trial of DCVax-L and Pembrolizumab (Keytruda) for colon cancer that was earlier announced.

Additionally, the Company’s product candidates include DCVax-Prostate. The design of this product is expressly for late stage, hormone independent prostate cancer. Northwest has developed a DCVax product line using a particular proprietary antigen — PSMA (Prostate Specific Membrane Antigen). It is found on essentially all late stage (hormone independent) prostate cancer. The PSMA is produced by way of recombinant manufacturing methods. It is then combined with the fresh, personalized dendritic cells to make DCVax-Prostate.

Northwest Biotherapeutics previously received clearance from the Food and Drug Administration (FDA) for a 612-patient Phase III trial in prostate cancer. It received approval in Germany of a five-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.

Northwest is also pursuing a Phase I/II trial with DCVax-Direct for all kinds of inoperable solid tumor cancers. The Company has completed the 40-patient Phase I portion of the trial. It is preparing the Phase II portion. Northwest earlier conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer in association with the University of Pennsylvania.

Last week, Northwest Biotherapeutics announced that on November 7, 2018, it completed an aggregate financing of $5 million from long term angel investors. Additionally, it agreed with Northwest`s Chief Executive Officer, Ms. Linda Powers, on further extensions of the Demand Notes relating to the $5.4 million of funding which Ms. Powers provided to Northwest in February, March and April of 2018 as a short-term bridge. The note proceeds are being used for continuing Company programs and operations.

Northwest Biotherapeutics, Inc. (NWBO), closed Monday's trading session at $0.2715, up 9.74%, on 7,678,918 volume with 953 trades. The average volume for the last 3 months is 1,184,900 and the stock's 52-week low/high is $0.17/$0.398.


Provectus Biopharmaceuticals, Inc. (PVCT)

Top Stock Analysts, plrinvest, Investors Underground, Real Pennies, PennyStocks24, Club Penny Stocks Network, The Street, Streetwise Reports, All Penny Stocks, Stock News Now, Wise Alerts, Top Penny Stock Movers, Street Insider, Street Authority Daily, and The Microcap News reported earlier on Provectus Biopharmaceuticals, Inc. (PVCT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Provectus Biopharmaceuticals, Inc. is a clinical-stage oncology and dermatology Biopharmaceutical Company. It is developing new therapies for the treatment of solid tumor cancers and dermatologic diseases. The Company`s investigational oncology drug is PV-10. PV-10 is an oncolytic immunotherapy enrolling patients in Phase 3 clinical trials for metastatic melanoma. Provectus Biopharmaceuticals is headquartered in Knoxville, Tennessee. The Company lists on the OTC Markets Group`s OTCQB.

PV-10 is an ablative immunotherapy under investigation in solid tumor cancers. PV-10 is a 10 percent solution of small molecule and halogenated xanthene Rose Bengal. It undergoes administration via direct injection into solid tumor cancers, such as melanoma, liver, and breast. It is not designed to rely on a single pathway, receptor or antigen to work. There is no known resistance.

The intention of PV-10 is to kill only diseased cells upon injection into tumors. Provectus has received orphan drug designations from the Food and Drug Administration (FDA) for its melanoma and hepatocellular carcinoma indications. Provectus completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

PH-10 is a topical investigational drug for dermatology. PH-10 is a topical hydrogel formulation. It yields selective delivery of rose bengal disodium to epithelial tissues. Pertaining to PH-10 for psoriasis and atopic dermatitis, a mechanism of action study is underway to measure the clinical and cellular response to PH-10's active investigational agent. A total of 226 subjects have been treated with PH-10 in Phase 1 or Phase 2 Clinical Trials.

Earlier this month, Provectus Pharmaceuticals announced that it was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for small molecule oncolytic immunotherapy PV-10 for the treatment of neuroblastoma, which is a non-Central Nervous System (CNS) pediatric solid tumor. Intratumoral injection of PV-10 can yield immunogenic cell death (ICD) in solid tumor cancers and stimulate tumor-specific reactivity in circulating T cells. ODD status previously was granted to PV-10 for the treatments of metastatic melanoma in 2007 and hepatocellular carcinoma (HCC) in 2013.

Provectus Biopharmaceuticals, Inc. (PVCT), closed Monday's trading session at $0.068, down 0.58%, on 453,462 volume with 42 trades. The average volume for the last 3 months is 248,003 and the stock's 52-week low/high is $0.0327/$0.092.


NewRange Gold Corp. (NRGOF)

InvestorsHub, Stockhouse, OTC Markets,, Junior Mining Network, Marketwired, PennyStockHub, Barchart, Stockwatch, OTC Bulls, and First Look Equities reported on NewRange Gold Corp. (NRGOF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

NewRange Gold Corp. concentrates on near to intermediate term production opportunities in favorable jurisdictions, including Nevada, Colorado and Colombia. An exploration and development company, it incorporated in 2006 as Colombian Mines Corporation, dedicated to exploring high quality mineral properties in Colombia.

In July 2016, it diversified into the U.S. through acquiring the high-grade Pamlico gold project in Nevada. OTCQB-listed, NewRange Gold is based in Vancouver, British Columbia. The Company changed its name to Newrange Gold Corp. in December of 2016.

NewRange Gold has its Pamlico Project in Mineral County, Nevada. In Colombia the Company has its El Dovio and Yarumalito projects.

The Pamlico Project is a high-grade epithermal gold system hosted in Jurassic to Tertiary age volcanic and sedimentary rocks. The project encompasses the historic Pamlico Mines on Pamlico Ridge, together with the Central, Sunset, Good Hope, Gold Bar and different unnamed mines and prospects.

Regarding the El Dovio project in Colombia, Newrange Gold holds 100 percent undivided interests in the mineral licenses, which encompass all potential mineralization at El Dovio. The Company purchased 100 percent of the surface rights covering the same ground at El Dovio.

The El Dovio property covers high-grade polymetallic gold-silver-copper-zinc mineralization in a belt of marine volcano-sedimentary rocks known to host other polymetallic and Volcanogenic Massive Sulfide (VMS) prospects and mines.

The Yarumalito Project in Colombia encompasses a large gold dominant porphyry complex composed of multiple intrusive centers. The property covers 1,456 hectares of highly prospective terrain, eleven air kilometers north of the famed Marmato District.

The Company owns a 100 percent undivided interest in the Contract Concession. Moreover, there are no underlying royalties or payments to third parties.

Last week, Newrange Gold announced drill final results for holes P17-33 through P17-40, the last eight holes from the 2017 Pamlico Phase II drill program. Drill holes P17-33, 34 and 35, all contain significant oxide gold intercepts. These confirm and extend high-grade mineralization along the K and J Zones trends within the Merritt target area. Individual samples from these three holes vary up to 56.7 g/T gold (Au). They also continue to highlight broader, lower grade, intervals of near surface bulk tonnage potential.

New Range Gold plans to commence the Phase III drill program this month. The drilling program will test new carbonate (sediment) and volcanic hosted gold targets across the Pamlico property.

Newrange Gold began trading on the OTCQB Venture Market in the United States under the symbol NRGOF effective at the beginning of trading on Wednesday, February 7, 2018.

NewRange Gold Corp. (NRGOF), closed Monday's trading session at $0.147, up 0.82%, on 300 volume with 1 trade. The average volume for the last 3 months is 35,787 and the stock's 52-week low/high is $0.05/$0.344.


The QualityStocks Company Corner

Sproutly Canada, Inc. (OTC: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF)., a global news source covering marijuana and hemp stocks and its cannabis podcast site report from Las Vegas at this year’s biggest MJBizCon show to date, from the first ever Podcaster’s Row. Today’s special edition features an interview with Dr. Arup Sen, the Chief Science Officer and Member of the Board of Directors for Sproutly Canada Inc. (CSE:SPR) (OTCQB:SRUTF) (38G.F). Also today, NetworkNewsWire released a report on the company detailing how SRUTF is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

Sproutly Canada, Inc. (OTC: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency worldwide.


Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTC: SRUTF), closed the day's trading session at $0.279, off by 6.75%, on 86,709 volume with 57 trades. The average volume for the last 3 months is 131,651 and the stock's 52-week low/high is $0.279/$1.875.

Recent News


Sharing Services, Inc. (SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Sharing Services (OTCQB: SHRV), a client of NNW and diversified holding company specializing in the direct selling industry. The interview can be heard at

Sharing Services, Inc. (SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders –  Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.31, up 14.81%, on 7,800 volume with 3 trades. The average volume for the last 3 months is 13,237 and the stock's 52-week low/high is $0.125/$0.589.

Recent News


CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY) announces that on Friday November 16, 2018 it completed the previously announced acquisition of privately held ProstaGene, LLC. Concurrently, Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and former Chief Executive Officer of ProstaGene, has been appointed to the CytoDyn board of directors and named Chief Medical Officer with responsibility for leading all PRO 140 (leronlimab) programs in non-HIV indications. Dr. Pestell has served as the Company’s Interim Chief Medical Officer since August 2018.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.6099, up 10.69%, on 366,223 volume with 114 trades. The average volume for the last 3 months is 233,635 and the stock's 52-week low/high is $0.40/$0.836.

Recent News


RYU Apparel, Inc. (TSX.V: RYU) (OTC: RYPPF) (FRA: RYA)

The QualityStocks Daily Newsletter would like to spotlight RYU Apparel, Inc. (RYPPF).

RYU Apparel Inc. (TSX VENTURE: RYU.V, OTCQB: RYPPF) ("RYU" or the "Company) broadcasted live from the New York Stock Exchange yesterday to mark the launch of its flagship US store. Aired on Cheddar TV, Marcello Leone, CEO of RYU, proudly announced the opening of the New York store as a further step in his US expansion plans.

Engineered for the fitness, performance and lifestyle of the athletically-minded, RYU Apparel, Inc. (DBA RYU \ Respect Your Universe) (TSX-V: RYU) (OTC: RYPPF) (FRA: RYA) develops, markets and distributes apparel, bags and accessories for active people living their lives with integrity. Headquartered in Vancouver, Canada, with with four stores located in Greater Vancouver Area, British Columbia and one in Toronto, RYU opened its first U.S.-based store at the iconic Abbot Kinney Boulevard in Venice California, on August 2, 2018. Additional retail locations are slated to open soon in Etokicoke, Ontario, Canada; Brooklyn, New York; and Newport Beach, California, with plans to establish nearly two dozen more store locations by the end of 2022.

Respect Your Universe’s award-winning brand celebrates, encourages and respects an individual’s choices and journey in life, promoting a fitness lifestyle culture. Innovatively designed without compromise and tailored for fit, comfort and durability, RYU exists to facilitate human performance. RYU’s urban athletic apparel and accessories product line has been featured by some of the most influential fitness and outdoor lifestyle publications and social media connectors.

The company recently was honored in Madrid, Spain, as a 2018 Finalist in the World Retail Awards in the categories of “Retail Start Up of the Year” and “Social Media Campaign of the Year,” (#RYUOneMoreRep). RYU is one of only two Canadian companies that qualified as finalists among many global retailers across all categories of the World Retail Awards annual event. The World Retail Awards have been recognizing the very best retailers and retail initiatives across a range of categories since 2007.

Marcello Leone, CEO of RYU, said the company’s inclusion in the prestigious lineup of finalists was gratifying, stating, “Being chosen by the World Retail Awards is a fantastic accolade. We are proud to be among a group of global peers that are considered to become the next generation of iconic brands. #RYUOneMoreRep Media Campaign is also another confirmation of the social aspect that permeates our brand and the impact we are having in our community.”

In addition to its retail locations, RYU generates sales through its e-commerce platform and has developed strategic relationships with companies such as Global-E, Netamorphosis, Fancy and the NHL Vancouver Canucks to expand its reach. RYU is also building connections with influential leaders and social media influencers who represent the company’s values of aliveness, bold expression, curiosity, discipline and respect. Under RYU’s Connector Program, each leader actively engages in community charities, volunteer efforts and participates in charity programs. Among the famous personalities and community leaders connecting with the RYU brand are:

  • Alexandra Ianculescu, a Canadian National Team Olympic Speed Skater
  • Ben Carr, professional trainer
  • Tori Katongo, personal trainer, singer, actor, dancer
  • Simon “Thor” Damborg, head coach at Raincity Athletics
  • Cassie Hawrysh, a Canadian National Team Skeleton Racer
  • Dai Manuel, lifestyle mentor and author of “The WholeLife Manifesto”

Company CEO Leon is the founder of Naturo Group Investment Inc., a company that sells nutritional beverages, and also is the former VP of operations and president of LEONE, an independent high fashion specialty store in Vancouver, Canada. Chief Financial Officer Pedro Villa is a certified CPA who has held several senior positions in various North American companies. Brett Pawson, senior VP of retail and operations, has more than 15 years of experience in sales and operations in the wellness, consumer goods and retail sectors.

RYU’s strategic focus is on becoming a global leader as a fitness and training apparel and accessories brand for athletes in multiple disciplines. RYU’s goal is to facilitate human performance by honoring and celebrating the extraordinary oneness of humanity by respecting each other’s differences – Respect Your Universe.

RYU Apparel, Inc. (RYPPF), closed the day's trading session at $0.104, up 3.17%, on 14,500 volume with 4 trades. The average volume for the last 3 months is 125,822 and the stock's 52-week low/high is $0.05/$0.255.

Recent News


DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

DPW Holdings, Inc. (NYSE American: DPW) today announced it has reached agreement with IAM, Inc. (“IAM”), owner of the Prep Kitchen brand of restaurants, to target for 2019 the addition of up to 4 locations and initiates for Prep Kitchen and its parent, an active growth plan over years to come. The program seeks to expand Prep Kitchen restaurant brand as well as include in the future other restaurant concepts. Also today, CryptoCurrencyWire released a report on the company detailing how reported financial results for its third quarter ended September 30, 2018. To view the full press release, visit:

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

  • The highest efficiency and highest density power converters and inverters
  • Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
  • Very high-frequency filters
  • Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

  • Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
  • Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
  • Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
  • Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
  • Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

  • Achieve compounded annual revenue growth of 25-35%
  • Achieve compounded annual net Income growth of 5%
  • Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.2521, up 0.32%, on 1,010,144 volume with 1,934 trades. The average volume for the last 3 months is 1,215,479 and the stock's 52-week low/high is $0.243/$5.949.

Recent News


Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (YGYI), a leading omni-direct lifestyle company announced that Carpe Canum Media released "The Audacity of Health: The Dr. Joel Wallach Story," a documentary on the Youngevity founder. It follows Dr. Wallach's life and career from his early work in the 1960's studying one of the first mass (animal) die-offs from pollution and helping to save the White Rhino in Africa, to his work in the 70's discovering the correlation between nutritional deficiencies in animals and disease, and how it extends into humans.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $6.67, off by 1.19%, on 65,291 volume with 435 trades. The average volume for the last 3 months is 545,176 and the stock's 52-week low/high is $3.167/$16.25.

Recent News


Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4)

The QualityStocks Daily Newsletter would like to spotlight Redfund Capital Corp. (PNNRF).

NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Redfund Capital Corp. (CSE: LOAN) (Frankfurt: O3X4) (OTC: PNNRF), a client of NNW focused on providing debt and equity funding in the mid-to-late stages of a target company’s development or in technologies that are developed and validated by revenues. The interview can be heard at Also today, NetworkNewsWire released a report on the company detailing how revenue-producing CBD operators that can scale successfully could turn to Redfund Capital for counsel and capital.

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4) is a merchant bank focused on providing debt and equity funding in the mid to late stages of a target company’s development and for technologies that are developed and validated by revenues. Redfund’s current focus is on medical cannabis, hemp and cannabidiol (CBD) related and healthcare-related companies.

As the first medical cannabis incubator and accelerator financing medical cannabis, CBD and hemp companies through a debt facility, Redfund is effectively bridging finance gaps and helping revenue-producing medical cannabis-related companies grow and build their valuations without prematurely diluting their equity.

The central components of the company’s business strategy are:

  • Establishing the foundation of a loan portfolio that generates revenues through monthly interest income from loans to cover all general and administrative expenses related to day-to-day operations.
  • Growing shareholder value by converting all or part of loans and warrants into equity in portfolio clients as clients build their valuations by entering the public markets or becoming the high-priced targets of larger entities.

Redfund was designed by bankers and entrepreneurs possessing years of experience in business, consulting, capital markets, corporate finance and healthcare services. The company is actively looking beyond borders and creating global companies that have strong fundamentals and are ready to expand.

Redfund’s investments are deployed to companies that have demonstrated success in their business but need a capital bridge in order to expand. Redfund’s team of professionals vet every project and analyzes each prospective client’s financials and business plans. Once a project is approved, Redfund’s legal team carefully scrutinizes the collateral used to securitize the individual loans.

The strategy employed by Redfund includes:

  • Diversifying investments in Canada and other countries
  • Building an international footprint with established national leaders
  • Funding new drug delivery systems and helping nutraceuticals become mainstream drugs
  • Introducing companies to Canada as a viable option for public listings
  • Becoming a premier go-to lender for established companies

The company’s revenue sources include:

  • Interest-bearing debt instruments with asset-backed collateral to securitize loans
  • Equity kicker of warrants coverage on original loan
  • Conversion ability of loan in its entirety
  • Advisory fees from contracts for consulting on growth strategies
  • Right of first refusal on future financing in each company funded

Redfund Capital Corp. (PNNRF), closed the day's trading session at $0.3836, even for the day. The average volume for the last 3 months is 1,014 and the stock's 52-week low/high is $0.244/$0.505.

Recent News


Canopy Rivers Inc. (TSX.V: RIV)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV).

Canopy Rivers Inc. (TSXV:RIV) congratulates its portfolio company, Radicle Medical Marijuana Inc. (“Radicle”), on receiving its production and sales licence from Health Canada. The licence will allow Radicle to supply and sell finished cannabis products for both the medical and adult-use market in Canada.

Canopy Rivers Inc. (TSX.V: RIV) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a premiere retail cannabis distributor that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Canada’s largest private liquor retailer, Solo Liquor, who collectively have more than 50 years of regulated substance retail experience. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy as “Solo Growth Corp.”
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $3.97, off by 0.75%, on 198,844 volume with 485 trades. The average volume for the last 3 months is 467,473 and the stock's 52-week low/high is $3.18/$11.82.

Recent News


First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

Vertically integrated North American pure-play cobalt company First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) (ASX: FCC) this morning announced drill results from its Idaho-based Iron Creek Cobalt Project that extend mineralization at depth and demonstrate additional mineralization between the two known zones and within the Waite Zone footwall. To view the full press release, visit: Also today, NetworkNewsWire released a report on the company detailing how FTSSF recently announced that it has begun testing cobalt hydroxide material as feedstock for its cobalt refinery (

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.2051, off by 2.33%, on 99,289 volume with 40 trades. The average volume for the last 3 months is 215,834 and the stock's 52-week low/high is $0.1382/$1.3041.

Recent News


BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

BriaCell Therapeutics Corp. (TSX-V: BCT) (OTCQB:BCTXF), is pleased to announce that Bria-IMT™ will be featured in a poster session during the 2018 San Antonio Breast Cancer Symposium (SABCS®) during December 4-8 in San Antonio, Texas. Also today, NetworkNewsWire released a report on the company detailing how BCTXF has been working hard on the advancement of its clinical program. The company attained crucial safety and efficacy data via its clinical trials, and it also achieved proof of concept.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.0894, off by 3.87%, on 4,160 volume with 3 trades. The average volume for the last 3 months is 19,328 and the stock's 52-week low/high is $0.068/$0.1387.

Recent News


SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint Inc. (OTC:SING), a fully reporting technology company providing mobile payments, ancillary cannabis services and blockchain solutions, reviews the week at MJBIZCON and provides an update to corporate initiatives. Last week SinglePoint management attended MJBIZCON meeting with potential partners and acquisitions. Video:

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.0208, off by 5.02%, on 5,068,559 volume with 148 trades. The average volume for the last 3 months is 4,570,523 and the stock's 52-week low/high is $0.019/$0.133.

Recent News


American Premium Water Corp. (HIPH)

The QualityStocks Daily Newsletter would like to spotlight American Premium Water Corp. (HIPH).

American Premium Water Corporation (OTC PINK: HIPH) (the "Company"), a diversified manufacturer, distributor and marketer of branded consumer products, announces it has signed and finalized a product license and sales distribution agreement with Canyon Create Corp. ("Canyon") (, the maker of Vanexxe, a varicose vein cosmetic masker, and Prickly Pear, a CBD-infused acne skin cream, among other patented topical and cosmetic technologies. This transaction was completed using restricted shares which cannot be traded for a year. Also today,, released an interview with Ryan Fishoff, CEO and Interim Chairman of American Premium Water Corporation (OTC: HIPH) from convention's first ever Podcast Row at MJBizCon.

American Premium Water Corp. (HIPH), headquartered in Playa Vista, California, is a diversified holding company, manufacturer, distributor and marketer of branded consumer products. HIPH, the acronym for “Hi-Power of Hydro,” maintains a portfolio of subsidiaries catering to the health-conscious consumer and luxury fashion brand connoisseur. The company’s two main pillars focus on the development of health and beauty biotech, dedicated to unlocking the power of hydrogen and nanotechnologies. Paired with cannabidiol or “CBD” in a unique beverage, the technology is proving to be a significant health and wellness option for astute consumers.

Among the company’s holdings are:

  • LALPINA Hydro beverages mix hydrogen with nanotechnology into consumer beverages that combine the best of health, nutrition and fitness to deliver short and long-term therapeutic health benefits. LALPINA Hydro utilizes atomic molecular hydrogen, or diatomic hydrogen, which converts antioxidants in the body to H2O to further enhance hydration, which helps increase endurance, reduce lactic acid and melt away fatigue. Over 500 peer-reviewed articles demonstrate hydrogen to have therapeutic potential in essentially every organ of the human body and in 150 different human disease models.
  • LALPINA Hydro CBD is a technically superior CBD-infused beverage. Using hydro and nanotechnology, LALPINA Hydro CBD encapsulates water molecules with cannabidiol molecules, making them infinitely more bioavailable and accelerating delivery to the body’s cells and tissues. Each bottle of LALPINA Hydro CBD contains 3 million nanograms of CBD free from the psychoactive compound THC (tetrahydrocannabinol). HIPH is the first to introduce a hydro-nano CBD-infused beverage on the market, which is a more effective delivery mechanism for administering CBD into the blood stream than traditional beverages or oils, with up to a 90 percent higher absorption rates.

The company recently signed a distribution agreement for its subsidiary, LALPINA Hydro CBD, to sell its beverages to two SinglePoint, Inc. (OTCQB: SING) e-commerce channels: and SING is a technology and investment company with a portfolio that includes mobile payments, blockchain solutions and ancillary cannabis services. HIPH will drop ship its product to the customers.

HIPH CEO Ryan Fishoff said the e-commerce arrangements “could bring in excess of a million of revenue over the life of the agreement.” The agreement serves as a pillar of the company’s e-commerce distribution strategy, driving awareness and impressions for the LALPINA brand.

In addition, HIPH seeks to market emerging fashion brands and leverage its relationship with classic retail partners while incorporating disruptive blockchain technologies to expand its retail footprint with the following:

  • Gents, a producer of luxury hats and other fine accessories and apparel, was acquired in September 2017. Gents is distributed across many luxury retail outlets including Saks Fifth Avenue, Bloomingdales, Nordstrom, and other high-end channels. The company added the Worthy streetwear brand to its portfolio in June 2018.
  • HIPH also acquired the license to operate the FashionCoinX exchange, a blockchain exchange focused on creating utility tokens for the fashion industry, and created THRD Coin, a multi-branded utility rewards token that is also the first token to be traded on the exchange. The company is leveraging its retail footprint and expertise in the fashion and apparel space with the burgeoning blockchain sector.

American Premium Water Corp. (HIPH), closed the day's trading session at $0.043, off by 9.09%, on 7,739,825 volume with 258 trades. The average volume for the last 3 months is 19,102,661 and the stock's 52-week low/high is $0.0035/$0.132.

Recent News


Cyberfort Software, Inc. (CYBF)

The QualityStocks Daily Newsletter would like to spotlight Cyberfort Software, Inc. (OTC: CYBF).

Cyberfort Software, Inc. (OTC PINK: CYBF), a cybersecurity technology company, today announces that it will apply for uplisting to the OTCQB® Venture Market in the first quarter of 2019. Also today, the company was highlighted in a report discussing the growing sophistication of cyber-attacks and repeated attempts at high-profile hacking have kept countries around the globe alert over the past few years. A series of cyber-attacks like WannaCry or WannaCrypt ransomware attacks and Petya rocked the globe.

Cyberfort Software, Inc. (CYBF) is a cybersecurity technology company specializing in the acquisition and development of security software, content filtering, and ad blocking technology. Headquartered in San Francisco, California, Cyberfort Software is actively dealing with various cyber threats through the development of innovative protection technologies designed for mobile, personal and business tech devices across multiple platforms.

Committed to the idea that everyone – from individuals to global corporations – should be able to enjoy a digital future free of malicious attacks robbing them of privacy and security, Cyberfort is working to strengthen its portfolio of cybersecurity IPs and stay one step ahead of cyberthreats. The growing plethora of tech devices enveloping everyday life opens the door to increasing cyberattacks through a stunning array of sophisticated cyberthreats. Protecting organizations and individuals with proactive security postures and protective measures is a key component of Cyberfort’s strategy to develop cybersecurity solutions that are smart, simple and efficient.

The company’s 2016 purchase of Vivio, a provider of pioneering AI content filtering and software protection, underscores Cyberfort’s commitment to cybersecurity. Vivio, an iOS 10 ad blocking app, currently serves over 10,000 unique users across iPhone, iPad and Mac. Vivio makes web browsing better, faster and more satisfying by blocking ads and reducing data usage, which also helps save battery life. Continuous ad blocking rule updates are delivered via an Intellectual Property Cloud-based autonomous engine with ad blocking tracker and malware detection filters.

Cyberfort recently signed a letter of intent to acquire Just Content Software which includes the Just Content app, software and underlying source code. Just Content is an efficacious and multi-functional ad blocking app that safeguards families and businesses with proprietary “Home Safe Filter” and “Business Filter” products. The Just Content app is available on iTunes and protects against unsafe links, adult content, phishing sites and inflammatory hate speech found on the internet, among other potential backdoor attacks and cyberthreats. A due diligence review is underway and a final determination regarding this acquisition is anticipated within weeks.

“Cyberfort aims to become a leader in developing cutting edge ad-blocking protective software that keeps the internet safe for families and business, which in our highly technological and immediate information-access society is a significant concern. Acquiring Just Content furthers our commitment to provide the best and most effective ad-blocking software in the marketplace,” says Cyberfort CEO Daniel Cattlin.

Favorable government regulations promoting tightened web security is a major factor driving adoption of web content filtering solution along with the public’s growing desire to better manage network bandwidth consumption and protect their online security and privacy. Cyberfort’s objective is to protect the data and integrity of personal and business computing assets and defend those assets against any threat or attack. The company’s software also offers symbiotic ad-blocking capabilities to complement its cyber defense effectiveness.

As Cyberfort continues to innovate, the Vivio team intends to leverage the current user base as a sandbox to test and optimize future incremental developments targeting an enterprise suite of tools that can be integrated into sector specific areas of growth. Key areas of focus include mobile device management, bring your own device (“BYOD”), mobile app management and secure mobile browser.

The Cyberfort leadership team is headlined by Cattlin, who offers a new age perspective to the business with expertise in project and asset management and a background in corporate finance. Cattlin brings both the operational and financial understanding to take companies from start-up and early development to expansion and capital growth within a public environment.

Chief Technology Officer Tomas Mistrik helped his team deliver a variety of technological products including the Vivio ad-blocking app for iOS 10 and the Silicon Valley-based Synergykit platform for mobile developers.

Technology Development Manager Krishna Kumar brings more than 10 years of experience in the Information Technology industry where he provided powerful security and ad-blocking measures for companies such as CSC and PayPal India.

Senior Advisor Harish Doddala brings nine years of product management and software engineering experience, delivering results for Cisco, VMware, Oracle, IBM and Siemens.

Cyberfort Software, Inc. (OTC: CYBF), closed the day's trading session at $0.42, off by 33.86%, on 20,639 volume with 26 trades. The average volume for the last 3 months is 21,527 and the stock's 52-week low/high is $0.051/$69.00.

Recent News


United Battery Metals Corp. (CSE: UBM) (OTC: UBMCF) (FWB: 0UL)

The QualityStocks Daily Newsletter would like to spotlight United Battery Metals Corp. (UBMCF).

United Battery Metals Corp. (CSE: UBM, OTC: UBMCF, FWB: 0UL) ("United Battery Metals" or the "Company") announces that the Canadian Securities Exchange has made the Company aware of promotional materials being distributed by Inult Alles Auf Anfang ("Inult") in Germany. Prior to being contacted by the CSE, the Company was unaware of Inult or the materials being distributed by Inult. Based on the information from the CSE, it appears that one of the principals of Inult is Helmut Pollinger, a principal of bullVestor Medien GmbH.

United Battery Metals Corp. (CSE: UBM) (OTC: UBMCF) (FWB: 0UL) is a vanadium exploration company focused on becoming the first vanadium producer in North America. The company’s flagship project is the Wray Mesa Project, an exploration-stage vanadium property located in Montrose County, Colorado. The property consists of over 107 contiguous mining claims on about 3000 acres. United Battery Metals recently announced that it has tripled its vanadium rich land package in Colorado and Utah. The claims are located on land where both the surface and mineral ownership is held by the Bureau of Land Management (BLM) of the U.S. Department of Interior. Valid unpatented mining claims grant the holder the right of mineral possession as allowed by the General Mining Law of 1872, subject to the various state and federal rules and regulations pertaining to mineral exploitation.

Global demand for vanadium as a strategic metal has exploded in recent years. Vanadium price surges have hit recent highs of approximately $22.63 per pound from about $9 per pound last year.? As a result, mining companies are returning to exploration efforts for vanadium.

The Wray Mesa Project area is part of the La Sal Creek District, which has a long history of exploration and production efforts with records showing drill exploration likely started there in the late 1940s with geologists from the U.S. Geological Survey (USGS) and the Atomic Energy Commission, then continued from the 1960s through the 1980s with private sector interests involved. Based on historical records, the Wray Mesa Project appears to have very good to excellent potential with an inferred resource of 500,000 pounds of uranium- and a current estimated vanadium resource of 2,640,000 pounds as per the last 43-101 prepared in 2013 by Anthony Adkins who is a qualified geologist.

The world’s vanadium demand is set to increase significantly as China implements tighter controls over this critical element as it is used in infrastructure to strengthen steel. With trade war tensions mounting, the U.S. will likely be in dire need of a domestic supply of vanadium for use in steel plants opening nationwide and grid power storage. In fact, the White House has deemed vanadium one of 35 critical elements to United States national and economic security (USGS). US Steel announced additional plants opening nationwide, and this bull market in domestic steel production is likely to increase the demand for a domestic source of vanadium as China has begun restricting vanadium exports to the U.S. amid mounting tensions between the two countries over tariffs and certain critical elements such vanadium.

UBM utilized resource estimation software to model the mineralization detected in a number of the 715 historical and 24 recent drill holes within the project area. Results of the model run, minus the estimated effects of the historic mining, identify an indicated resource of approximately 85,500 short tons at an average grade of 0.16% eU308 for a total of 271,000 pounds of contained uranium. Inferred resources total 57,400 short tons at an average grade of 0.15% of eU308 for a total of about 169,000 pounds of contained uranium. The vanadium resource for the two categories, based on a conservative V:U ratio of 6:1, is 1,626,000 (O.95% average grade) and 1,014,000 (0.88% average grade) pounds, respectively.

Vanadium has multiple uses in modern society including being used in vanadium redox flow batteries (“VRFBs”), car charging stations, nuclear power plants and in steel manufacturing. An article in notes that vanadium pentoxide (V2O5), which is used in the production of VRFBs used in energy storage systems, breached US$20 a pound in September 2018 for the first time since 2005, a four-fold increase from the start of 2017.

California recently announced that all homes and mid rises must install solar panels by 2020. Vanadium redox flow batteries (VRFBs) are by far the most superior batteries for large scale energy storage systems and the reason why the Vanadium Redox Flow batteries will dwarf the lithium battery demand. California was the first to announce this green initiative and many experts expect that the revolution will be implemented nationwide in the near future.

Vanadium is one of the 35 minerals deemed critical to the national security and economy of the United States. Among the important uses of vanadium are the following:

  • Fast-charging VRFBs have unique characteristics making them especially attractive when compared to conventional batteries. VRFBs can operate at any temperature, be charged and discharged at the same time, have greater design flexibility and a 25-plus year lifecycle. VRFB’s promise to be a major player in the green energy storage revolution because they are 100 percent reusable, recyclable, are nonflammable, compact, able to provide large grid energy storage, can be fully contained and are seen as a viable alternative to lithium-ion batteries.
  • VRFBs can be used in a variety of energy storage applications including microgrids, during peak shaving periods and for load leveling, as an uninterruptible power supply, for wind and solar farms, and as an off-grid power supply.
  • Approximately 85 percent of vanadium produced is used as ferrovanadium or as an additive to strengthen and harden steel used for applications in axles, crankshafts, gears, surgical instruments and tools, knives, jet engines, high-speed airframes, dental implants, and in seamless tubing for the aerospace, defense and bicycle industries.
  • Vanadium alloys are used in nuclear reactors because of the metal’s low neutron-absorbing properties.

The management team at United Battery Metals Corp. includes president, CEO and Director Matthew Rhoades, the former State Geologist for New Mexico and an accomplished professional geologist with direct working experience in exploration and development projects at numerous deposits and mines throughout the American West, Canada, Mexico and South America. He is joined by George Sharpe, a qualified Mineral Exploration Geoscientist, QP, MCIM and CGT, with over 23 years of global mineral exploration in iron coal, gold, base metals, rare earths, uranium, PGE’s, diamonds, iron and industrial minerals.

United Battery Metals Corp. (UBMCF), closed the day's trading session at $0.40, off by 6.15%, on 626,697 volume with 582 trades. The average volume for the last 3 months is 110,971 and the stock's 52-week low/high is $0.40/$1.58.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.